Nerofe
Nerofe is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
64 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 5 | 8 | 1 | — | 1 | 13 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 5 | 2 | — | — | 8 |
| Triple negative breast neoplasms | D064726 | — | — | 3 | 5 | 1 | — | — | 7 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 2 | 2 | — | — | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 4 | 1 | — | — | 5 |
| Uterine cervical neoplasms | D002583 | — | — | 1 | 3 | 1 | — | — | 4 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 1 | 1 | — | 2 | 4 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 1 | 1 | — | — | 2 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 1 | 1 | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 11 | 6 | — | — | — | 13 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 4 | — | — | — | 5 |
| Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | 2 | 4 |
| Colorectal neoplasms | D015179 | — | — | 3 | 4 | — | — | — | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 4 | — | — | — | 4 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 3 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 1 | 2 | — | — | 1 | 3 |
| Squamous cell carcinoma | D002294 | — | — | — | 3 | — | — | — | 3 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 1 | — | — | 2 | 3 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 2 | — | — | — | 2 |
Show 28 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | — | — | — | 1 | 2 |
| Multiple endocrine neoplasia type 2a | D018813 | — | E31.22 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | — | — | — | — | 1 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 1 | — | — | — | — | 1 |
| Pseudomyxoma peritonei | D011553 | EFO_0007456 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Hypoxia | D000860 | — | R09.02 | — | — | — | — | 1 | 1 |
| Hyperoxia | D018496 | — | — | — | — | — | — | 1 | 1 |
| B-cell lymphoma | D016393 | — | — | — | — | — | — | 1 | 1 |
| Burkitt lymphoma | D002051 | — | C83.7 | — | — | — | — | 1 | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nerofe |
| INN | _ |
| Description | Nerofe is a protein pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@@H](NC(=O)[C@H](NC(=O)[C@@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](N)Cc1c[nH]c2ccccc12)C(C)O)C(C)O)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297308 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | SR717JCM7M (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use